摘要
为了探讨原发女性生殖系统恶性淋巴瘤（primary female genital system lymphoma，PFGSL）的临床特点、治疗方法及预后，回顾性分析1991～2004年收治的21例原发女性生殖系统恶性淋巴瘤临床资料。结果显示PFGSL占同期恶性淋巴瘤的0。7％，以宫颈恶性淋巴瘤最为常见，占61．9％；病理类型以B细胞采源为主，占66．7％。治疗方法采用手术、化疗和放疗相结合的综合治疗。全组患者中位生存时间（MST）21个月，5年生存率19．0％。PFGSL预后与分期、原发部位有一定关系，晚期病例（MST11个月）的预后明显差于早期病例（MST5年），两者差异有统计学意义，P=0．0004。原发卵巢的患者MST仅8个月，预后最差；原发子宫及阴道的相对较好，MST50个月，两者相比有统计学意义，P=0．0019。初步研究结果提示，PFGSL是罕见的结外淋巴瘤，治疗方法应采用化疗及手术为主的综合治疗，分期及原发部位是预后的影响因素。
The objective of this study was to explore the clinical characteristics, reasonable mode of treatment and prognostic factors in patients with primary female genital system lymphoma （PFGSL）. The clinical data of 21 patients with PFGSL treated from 1991 to 2004 were retrospectively reviewed. PFGSL accounted for 0.7% of all non-Hodgkin＇s lymphomas presented in the corresponding period. It mainly involved cervix uterus with a percent of 61.9%, and 66.7% of the patients were dignosed as having B-cell origin by immunophenotyping. Most patients received comprehensive treatment including surgery, chemotherapy and/or irradiation. The median follow-up of the surviving patients was 21 months. The 5-year overall survival rate was 19.0%. Ann Arbor stage and the involved organs were significant prognostic factors for survival （P=0. 000 4, P=0. 001 9）. Our results show that PFGSL is a rare entity of extranodal lymphoma. Chemotherapy plays a very important role in comprehensive treatment. The significant prognostic factors for survival are stage and the involved original organs.
出处
《中华肿瘤防治杂志》
CAS
2006年第19期1511-1512,共2页
Chinese Journal of Cancer Prevention and Treatment
